Vanda Pharmaceuticals (VNDA) Assets Average (2011 - 2026)

Vanda Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $461.2 million for Q1 2026.

• Assets Average for Q1 2026 came in at $461.2 million, down 28.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $461.2 million (down 28.39% YoY), and the FY2025 annual result was $572.6 million, down 12.22% from the prior year.
• Assets Average came in at $461.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $545.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $652.0 million in Q2 2024 to a low of $461.2 million in Q1 2026.
• The 5-year median for Assets Average is $639.4 million (2023), against an average of $618.3 million.
• Across the five-year window, Assets Average grew 11.21% in 2022 and retreated 28.39% in 2026, its largest moves.
• Vanda Pharmaceuticals' Assets Average stood at $628.0 million in 2022, then increased by 2.71% to $645.0 million in 2023, then increased by 0.87% to $650.7 million in 2024, then slipped by 16.23% to $545.0 million in 2025, then fell by 15.38% to $461.2 million in 2026.
• The last three Assets Average figures came in at $461.2 million (Q1 2026), $545.0 million (Q4 2025), and $612.9 million (Q3 2025), per Business Quant data.